New approaches to treating Alzheimer's disease
Hailin Zheng1, Mati Fridkin2, Moussa Youdim3
1Department of Medicinal Chemistry, Intra-cellular Therapies Inc., New York, NY, USA.
Perspectives in Medicinal Chemistry
|March 4, 2015
Summary
New network medicine approaches offer hope for Alzheimer's disease (AD) treatment by targeting multiple pathways simultaneously. Several multi-target drug candidates show potential for holistic, disease-modifying effects in AD therapy.
Area of Science:
- Neuroscience
- Pharmacology
- Systems Biology
Background:
- No effective Alzheimer's disease (AD) drugs have been developed since 2003.
- Traditional single-target approaches have consistently failed in AD drug development.
Purpose of the Study:
- To explore network medicine as a novel therapeutic strategy for Alzheimer's disease.
- To identify potential multi-target drug candidates for AD treatment.
Main Methods:
- Discussing network medicine's principle of simultaneous modulation of disease-disrupted networks.
- Reviewing drug candidates like Keap1-Nrf2 regulators, endogenous neurogenic agents, and HIF-1 activators.
- Analyzing their multi-target ligand properties and role as master regulators.
Main Results:
- Network medicine offers a holistic approach by targeting multiple proteins and pathways in AD pathogenesis.
- Identified drug candidates possess multi-target capabilities, initiating broad cellular defense mechanisms.
- These candidates demonstrate potential for disease-modifying effects beyond single-target treatments.
Conclusions:
- Network medicine represents a promising new paradigm for Alzheimer's disease therapy.
- Multi-target ligands acting as master regulators are key candidates for developing effective network medicines.
- This approach may significantly advance Alzheimer's drug discovery and development.
Keywords:
AChE-MAO-A/B inhibitorAlzheimer’s diseaseHIF-1 activatorKeap1–Nrf2 regulatorM30neurogenic agentsMore Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
914
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
914
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:28Drug Therapy
418
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
418
01:15Parkinson's Disease: Overview
2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K